rolipram has been researched along with Diabetes Mellitus, Type 1 in 2 studies
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rolipram was inhibitory at concentrations as low as 10(-8) to 10(-7) mol/l, and on a molar basis, it was 100-fold more effective than PTX." | 1.30 | The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. ( Beshay, E; Liang, L; Prud'homme, GJ, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, L | 1 |
| Beshay, E | 2 |
| Prud'homme, GJ | 2 |
| Croze, F | 1 |
2 other studies available for rolipram and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antibodies, Monoclonal; CD3 Complex; Cyclic Nucleotide | 1998 |
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Autoimmune Diseases; Bucladesine; Cells, Cultured; | 2001 |